[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-alopecia-areata\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-alopecia-areata":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100604638","a-study-to-learn-about-litfulo-capsule-in-people-with-severe-alopecia-areata-in-routine-clinical-practice-100604638",false,"NCT07152119","A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.","KOREAN POST MARKETING SURVEILLANCE FOR LITFULO CAPSULE","Inclusion Criteria:\n\nPatients with severe alopecia areata who have been determined to start treatment with Litfulo Capsule according to the approved indications of the medicinal product Treatment of severe alopecia areata in adults and adolescents 12 years or older Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)\u002Flegal guardian, if applicable, have been informed of all pertinent aspects of the study","ALL","12 Years",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.",[24],"Severe Alopecia Areata",[26,27,28],"Litfulo","Litfulo capsule","Ritlecitinib tosylate","RECRUITING","2026-05-14",{"date":32,"type":33},"2026-05-18","ACTUAL",{"date":35,"type":33},"2025-08-27",{"date":37,"type":20},"2030-03-23",{"name":39,"class":40},"Pfizer","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100635556","phase-1-study-to-evaluate-the-safety-tolerability-and-how-ibi3013-is-taken-up-and-processed-by-the-body-in-healthy-volunteers-after-single-dose-administration-and-in-non-segmental-vitiligo-patients-and-alopecia-areata-patients-after-multiple-dose-administration-100635556","NCT07554222","Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration","Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study","Inclusion criteria\n\n1. Part 1 - Healthy trial participants: Understand and voluntarily sign the informed consent form;\n2. Part 1 - Healthy trial participants: Age between 18-45 years (inclusive), male or female;\n3. Part 1 - Healthy trial participants: Weight between 50-120 kg (inclusive), and BMI between 17.0-28.0 kg\u002Fm2 (inclusive);\n4. Part 2 - Active non-segmental vitiligo trial participants: 18-65 years old (inclusive), male;\n5. Part 2 - Active non-segmental vitiligo trial participants: Diagnosed with non-segmental vitiligo for ≥3 months and \\\u003C2 years;\n6. Part 2 - Active non-segmental vitiligo trial participants: Total affected BSA 3-50%, and facial affected BSA ≥ 0.5%; T-VASI 3-50 (inclusive), and F-VASI ≥0.5; ≥1 active lesion;\n7. Part 2 - : Male participants of reproductive potential agree to use highly effective contraception and avoid sperm donation for 6 months after the last dose.\n8. Part 2 - Severe alopecia areata trial participants: 18-60 years old (inclusive), male;\n9. Part 2 - Severe alopecia areata trial participants: Meet the following severe alopecia areata criteria: a) SALT ≥50% (i.e., AA-IGA 3-4 grade) b) No spontaneous remission in the past 6 months (spontaneous remission defined as SALT reduction by ?10 points) c) Current duration of severe alopecia areata ≥6 months and \\\u003C4 years;\n10. All participants: Participants of reproductive potential agree to use highly effective contraception and avoid sperm or egg donation for 6 months after the last dose.\n\nExclusion criteria\n\n1. All participants: Those who are allergic to any component of IBI3013;\n2. All participants: Those who cannot tolerate subcutaneous injection;\n3. All participants: History of live or attenuated live vaccine within 30 days prior to randomization, or expected to receive such vaccines during the study period until 3 months after the last dose of the investigational drug;\n4. All participants: Donated blood or lost ≥400 mL of blood within 3 months before screening;\n5. All participants: History of herpes zoster or disseminated herpes simplex (single episode), or recurrent (more than one episode) localized herpes zoster;\n6. All participants: Known history of active tuberculosis or clinical manifestations suggestive of tuberculosis, or positive interferon-gamma release assay unsuitable for participation;\n7. All participants: Abnormal vital signs, serum virology tests, laboratory tests, ECG, or other examinations with clinical significance, and deemed unsuitable for the study by the investigator;\n8. All participants: Received specific treatment within the time frame specified in the protocol, or participated in other investigational drug studies within the specified time;\n9. All participants: History of drug abuse, drug dependence, or positive drug screening results during the screening period within 12 months;\n10. All participants: Pregnant or lactating women;\n11. All participants: Coexisting diseases at screening or previously, deemed unsuitable for clinical trials;\n12. Active non-segmental vitiligo\u002FSevere alopecia areata trial participants: Previous or coexisting diseases, which may affect the efficacy or safety evaluation of the study as assessed by the investigator;\n13. Active non-segmental vitiligo trial participants: Coexisting segmental, undetermined type, or mixed-type vitiligo, or other skin pigmentation disorders, or other skin-related abnormalities that may affect the assessment of the study;\n14. Severe alopecia areata trial participants: Currently diagnosed with primary diffuse AA or ophiasis AA; or other types of hair loss that may interfere with AA evaluation;\n15. Severe alopecia areata trial participants: Previously received oral JAK inhibitors with poor response; 16. Severe alopecia areata trial participants: Acute myocardial infarction, unstable ischemic heart disease, stroke, chronic heart failure (NYHA class III\u002FIV) within 12 weeks prior to screening; or previous history of deep vein thrombosis, or high risk of deep vein thrombosis as assessed by the investigator; or severe neuropsychiatric disorder, deemed unsuitable for the study by the investigator.",true,"18 Years","80 Years",{"count":53,"type":20},160,"INTERVENTIONAL",[56],"PHASE1","A multicenter clinical study to evaluate the safety, PK characteristics, immunogenicity characteristics, and PD characteristics of IBI3013 in healthy trial participants and active non-segmental vitiligo trial participants and severe alopecia areata trial participants. The study is divided into 2 parts, with Part 1 involving healthy trial participants lasting up to 24 weeks, and Part 2 involving active non-segmental vitiligo trial participants and severe alopecia areata trial participants lasting up to 48 weeks.",[59,60,24],"Healthy","Active Non-segmental Vitiligo","2026-04-23",{"date":63,"type":33},"2026-04-28",{"date":65,"type":33},"2026-04-18",{"date":67,"type":20},"2028-12-31",{"name":69,"class":40},"Innovent Biologics (Suzhou) Co. Ltd.",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100595236","phase-3-a-long-term-study-to-learn-about-the-study-medicine-called-ritlecitinib-in-children-with-severe-alopecia-areata-100595236","NCT07029828","A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.","A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031","B7981028","Inclusion Criteria:\n\n1. Participants with alopecia areata (AA) (including alopecia totalis \\[AT\\] and alopecia universalis \\[AU\\]) who completed the studies B7981027 or B7981031.\n2. For participants originating from Study B7981031: At least 50% scalp hair loss due to AA (ie, a SALT score of ≥50) at both the Screening and Baseline visits.\n\nExclusion Criteria:\n\n1. Exclusion criteria for participants originating from Study B7981027 with ≤ 30 Days between last dose in Study B7981027 and first visit of Study B7981028\n\n   1. During Study B7981027 or in the period between the last dose of study intervention in Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol.\n   2. Study participants discontinued from Study B7981027 due to issues other than safety-related events and considered by the investigator for enrolment in Study B7981028 must have resolution of the issue(s) resulting in discontinuation from the parent study prior to enrolment in Study B7981028.\n2. Exclusion criteria for participants originating from Study B7981031 or from Study B7981027 with \\>30 Days between last dose in Study B7981027 and first visit of Study B7981028\n\n   1. During Study B7981031 or Study B7981027 or in the period between the last dose of study intervention in Study B7981031 or Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol.\n   2. Any present malignancies or history of malignancies or lymphoproliferative disorders.\n   3. Evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection, history (one or more episodes) of severe or serious cytomegalovirus (CMV), herpes zoster (shingles) or disseminated herpes simplex, infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).\n\n      \\-","6 Years","14 Years",{"count":81,"type":20},140,[83],"PHASE3","The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.\n\nThis study is seeking participants who have:\n\n* previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031).\n* at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031).\n* received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports.\n\nAll participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial.\n\nParticipants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial.\n\nThe study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home.\n\nThe study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.",[24],[87,88,89,90],"Alopecia Areata","Children","Ritlecitinib","Long-term extension study",{"date":63,"type":33},{"date":93,"type":33},"2025-09-10",{"date":95,"type":20},"2030-06-26",{"name":39,"class":40},41,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":54,"phases":108,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":114,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100559343","phase-2-study-to-evaluate-safety-and-efficacy-of-syhx1901-tablets-in-severe-alopecia-areata-patients-100559343","NCT06562894","Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients","A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata","Inclusion Criteria:\n\n1. Subjects fully understand and voluntarily participate in this study and sign informed consent;\n2. Subjects aged ≥18 to ≤ 65 years;\n3. Clinical diagnosis of alopecia areata,with at least 50% scalp hair loss，as defined by a SALT score ≥50 at screening and baseline visit;\n4. The current episode of hair loss was less than 10 years ago, and there was no evidence of spontaneous hair regrowth within 6 months before screening (the overall duration of alopecia areata more than 10 years could be included);\n5. Subjects must be volunteer and be able to understand informed consent Forms;\n6. Subjects and their partners should voluntarily take contraceptive measures considered effective by the investigator during the study period and for at least 28 days after the study;\n\nExclusion Criteria:\n\n1. Participants who have received hair implants;\n2. Alopecia caused by other reasons;\n3. Other active scalp or systemic diseases that may cause severe alopecia or affect the clinical evaluation of alopecia areata;\n4. Participants who have shaved their heads;\n5. Participants who have a clinically significant (as assessed by the investigator) abnormality in TSH or free T4 at screening and who were deemed by the investigator to be ineligible for the study;\n6. Participants who wore stick-on wigs and refused to stop wearing them during the study;\n7. Bacterial, fungal, or viral infection requiring hospitalization\u002Fintravenous treatment within 4 weeks before the first dose of study drug or requiring oral treatment within 2 weeks before the first dose of study drug;\n8. Have any chronic infection that requires systemic anti-infective therapy;\n9. Have received a live vaccine within 60 days before the first dose of the study drug or plan to receive a live vaccine between the middle of the study and 60 days after the end of the study;\n10. History of severe herpes zoster or sever herpes simplex infection;\n11. HBV-related tests are abnormal at screening;\n12. HCV antibody positive and HCV RNA positive at screening;\n13. Human immunodeficiency virus antibody positive or treponema pallidum antibody positive;\n14. Any known or suspected condition of congenital or acquired immunodeficiency;\n15. Previous or current active tuberculosis infection or latent tuberculosis infection (LTBI) deemed by the investigator\u002Fspecialist to require treatment;\n16. Major surgery within 8 weeks prior to first dose of the study drug or planned surgery during the study;\n17. Organ transplantation (except corneal transplantation more than 3 months before the initiation of the investigational drug);\n18. Symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with other chronic diseases that the investigator has determined are not suitable for participation in this clinical trial;\n19. History of malignancy or lymphoproliferative disease;\n20. Uncontrolled hypertension, systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg after systemic treatment;\n21. Having unstable cardiovascular disease defined as presence of a clinical cardiovascular event in the last 3 months or hospitalized for heart disease within the last 3 months; or NYHA≥grade 3, or abnormal ECG suggesting clinically significant and assessed by the investigator as carrying unforeseen risks;\n22. Patients with a history of arterial or venous thrombosis or high risk factors for thrombosis within 6 months before the first dose of study drug;\n23. Combined with active lipid-lowering drugs but poorly controlled hyperlipidemia: total cholesterol (TC)≥ 6.2mmol\u002FL or low-density lipoprotein cholesterol (LDL-C)≥3.4mmol\u002FL; or familial hypercholesterolemia (FH);","65 Years",{"count":107,"type":20},156,[109],"PHASE2","The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of severe alopecia areata.",[24],[113],"plaque psoriasis","NOT_YET_RECRUITING","2025-05-28",{"date":117,"type":33},"2025-06-03",{"date":119,"type":20},"2025-05-26",{"date":121,"type":20},"2027-11-17",{"name":123,"class":40},"CSPC Ouyi Pharmaceutical Co., Ltd."]